The Wall Street Transcript Interviews Nutra Pharma Chairman and CEO

Nutra Pharma’s Chairman and CEO, Rik J Deitsch, Has Been Interviewed for the Pharmaceutical Issue of the Wall Street Transcript. In the Interview, Mr. Deitsch Discusses the Company’s Recent Accomplishments, Its Upcoming Launch of Cobroxin, and Its Future Growth Opportunities.

• Press Release
• Source: Nutra Pharma Corp.
• On 9:00 am EDT, Thursday September 24, 2009

PLANTATION, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB: NPHC - News), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J Deitsch, has been interviewed for the Pharmaceutical Issue of The Wall Street Transcript.

Related Quotes

Symbol	Price	Change
NPHC.OB	0.43	+0.01

{"s" : "nphc.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

“With the impending launch of our first biopharmaceutical product, Cobroxin, and our transition from a research and development stage biotechnology company into a revenue-producing company, it is now more important than ever that we share our story with the investment community,” explained Mr. Deitsch. “As a highly-respected financial publication, The Wall Street Transcript provides the perfect outlet to communicate with retail and institutional investors,” he added.

In the interview, Mr. Deitsch discusses Nutra Pharma's launch of Cobroxin, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain. In addition, he outlines the company’s recent accomplishments and the company’s growth opportunities with its drug discovery pipeline and potential strategic acquisitions.

The Wall Street Transcript is one of the country’s leading financial publications, reaching over 200,000 readers each month through its website and its printed magazine. Its subscriber base represents some of the top money managers, investment brokers, and corporations in the United States. The Pharmaceutical Issue, which features the interview with Mr. Deitsch, will be published and available in November 2009.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

http://www.Cobroxin.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Rik J. Deitsch’s interview in the Pharmaceutical Issue of the Wall Street Transcript should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Nutra Pharma Corp.
David Isserman, 877-895-5647
IR@nutrapharma.com